The past 18 months haven’t been very pleasant for biotech investors. The SPDR S&P Biotech ETF (NYSEMKT: XBI) has fallen nearly 30% from its all-time highs set back in the summer of 2015. Many individual biotech stocks have performed far worse.
One bright side to all of that selling is that a handful of high-quality biotech stocks are currently trading for attractive prices. With that in mind, here’s a look at three biotech stocks that I think are well positioned to outperform in the new year.